儿童获得性再生障碍性贫血的治疗进展  

Progress in the treatment of acquired aplastic anemia in children

作　　者：王忠健 邱奕宁 金润铭[1] Wang Zhongjian;Qiu Yining;Jin Runming(Department of Pediatrics,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院儿科,武汉430022

出　　处：《国际儿科学杂志》2022年第12期804-808,共5页International Journal of Pediatrics

摘　　要：再生障碍性贫血(aplastic anemia,AA)是一种外周血两系或三系减少的骨髓衰竭性疾病,临床上患者出血、感染风险高,严重时危及生命。由于全球各地区经济条件、医疗条件、AA流行病学等存在较大差异,因此关于初诊、难治/复发性AA患者的治疗方法众多且疗效不一。治疗方法中的单倍体造血干细胞移植、艾曲波帕和他克莫司是近几年的研究热点。为方便临床医师选择更合适的治疗方法,该文对AA患者造血干细胞移植治疗和非移植治疗的研究进展进行综述。Aplastic anemia(AA)is a bone marrow failure disease in which peripheral blood is reduced in two or three lines.Clinically,patients are at high risk of bleeding and infection,which may endanger their lives in serious cases.Due to the great differences in economic conditions,medical conditions and AA epidemiology in various regions around the world,there are many treatment methods for newly diagnosed,refractory/relapsed AA patients and their curative effects are different.Haploidentical hematopoietic stem cell transplantation,eltrombopag and tacrolimus are the research focuses in recent years.To facilitate clinicians to choose more appropriate treatments,this paper reviews the progress of hematopoietic stem cell transplantation therapy and non-transplantation therapy in patients with AA.

关 键 词：儿童 再生障碍性贫血 造血干细胞移植 艾曲波帕 他克莫司 

分 类 号：R725.5[医药卫生—儿科]